Latest & greatest articles for Benign Prostatic Hyperplasia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on Benign Prostatic Hyperplasia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on Benign Prostatic Hyperplasia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for Benign Prostatic Hyperplasia

101. Cost effectiveness of treatment for benign prostatic hyperplasia: an economic model for comparison of medical, minimally invasive, and surgical therapy

Cost effectiveness of treatment for benign prostatic hyperplasia: an economic model for comparison of medical, minimally invasive, and surgical therapy Cost effectiveness of treatment for benign prostatic hyperplasia: an economic model for comparison of medical, minimally invasive, and surgical therapy Cost effectiveness of treatment for benign prostatic hyperplasia: an economic model for comparison of medical, minimally invasive, and surgical therapy Manyak M J, Ackerman S J, Blute M L, Rein (...) A L, Buesterien K, Sullivan E M, Tanio C P, Strauss M J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Three therapies for benign prostatic hyperplasia (BPH) were compared. The three therapies were medical therapy (alpha-blocker

2002 NHS Economic Evaluation Database.

102. Microwave thermotherapy for benign prostatic hyperplasia</a>

Microwave thermotherapy for benign prostatic hyperplasia Microwave thermotherapy for benign prostatic hyperplasia We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Swedish Agency for Health Technology Assessment and Assessment of Social Services Microwave thermotherapy for benign prostatic hyperplasia Share: Reading time approx. 6 minutes This document was published more than 2 years ago. The nature of the evidence may have (...) changed. Findings by SBU Alert Version: 2 Technology and target group Symptomatic benign prostatic hyperplasia (BPH) is common among older males. In transurethral microwave thermotherapy (TUMT) for BPH, a special catheter equipped with a microwave antenna is inserted in the urethra. The aim is to reduce the enlargement by using heat to destroy tissue in the prostate. An early variant of this treatment method (low-energy TUMT) was introduced in Sweden in the early 1990s. Many patients experienced

2002 Swedish Council on Technology Assessement

103. Beta-sitosterols for benign prostatic hyperplasia. (Abstract)

Beta-sitosterols for benign prostatic hyperplasia. This systematic review aimed to assess the effects of beta-sitosterols (B-sitosterol) on urinary symptoms and flow measures in men with of benign prostatic hyperplasia (BPH).Trials were searched in computerized general and specialized databases (MEDLINE, EMBASE, Cochrane Library, Phytodok), by checking bibliographies, and by contacting manufacturers and researchers.Trials were eligible for inclusion provided they (1) randomized men with BPH (...) changes in nocturia as well as urodynamic measures (peak and mean urine flow, residual volume, prostate size). Main outcome measure for side effects was the number of men reporting side effects.519 men from 4 randomized, placebo-controlled, double-blind trials, (lasting 4 to 26 weeks) were assessed. 3 trials used non-glucosidic B-sitosterols and one utilized a preparation that contained 100% B-sitosteryl-B-D-glucoside. B-Sitosterols improved urinary symptom scores and flow measures. The weighted mean

2000 Cochrane

104. Cernilton for benign prostatic hyperplasia. (Abstract)

Cernilton for benign prostatic hyperplasia. Benign prostatic hyperplasia (BPH), nonmalignant enlargement of the prostate, can lead to obstructive and irritative lower urinary tract symptoms (LUTS). The pharmacologic use of plants and herbs (phytotherapy) for the treatment of LUTS associated with BPH has been growing steadily. Cernilton, prepared from the rye-grass pollen Secale cereale, is one of the several phytotherapeutic agents available for the treatment of BPH.This systematic review aims (...) to assess the effects of Cernilton on urinary symptoms and flow measures in men with benign prostatic hyperplasia (BPH).Trials were searched in computerized general and specialized databases (MEDLINE, EMBASE, Cochrane Library, Phytodok), by checking bibliographies, and by contacting manufacturers and researchers.Trials were eligible if they were: (1) randomized controlled trials or controlled clinical trials comparing Cernilton with placebo or other BPH medications in men with BPH; and (2) included

2000 Cochrane

105. Serenoa repens for benign prostatic hyperplasia. Full Text available with Trip Pro

Serenoa repens for benign prostatic hyperplasia. This systematic review aimed to assess the effects of Serenoa repens in the treatment of Benign Prostatic Hyperplasia (BPH).Trials were searched in computerized general and specialized databases (MEDLINE, EMBASE, Cochrane Library, Phytodok), by checking bibliographies, and by contacting manufacturers and researchers.Trials were eligible if they (1) randomized men with BPH to receive preparations of Serenoa repens (alone or in combination

2000 Cochrane

106. Cost effectiveness of microwave thermotherapy in patients with benign prostatic hyperplasia. Part I: methods

Cost effectiveness of microwave thermotherapy in patients with benign prostatic hyperplasia. Part I: methods Cost effectiveness of microwave thermotherapy in patients with benign prostatic hyperplasia. Part I: methods Cost effectiveness of microwave thermotherapy in patients with benign prostatic hyperplasia. Part I: methods Ackerman S J, Rein A L, Blute M, Beusterien K, Sullivan E M, Tanio C P, Manyak M J, Strauss M J Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Microwave thermotherapy in patients with benign prostatic hyperplasia. Type of intervention Treatment. Economic study type Cost-utility analysis. Study population The study population comprised a hypothetical cohort of 10,000 65-year-old men with moderate

2000 NHS Economic Evaluation Database.

107. Transurethral microwave thermotherapy (TUMT) for benign prostatic hyperplasia

Transurethral microwave thermotherapy (TUMT) for benign prostatic hyperplasia Transurethral microwave thermotherapy (TUMT) for benign prostatic hyperplasia Transurethral microwave thermotherapy (TUMT) for benign prostatic hyperplasia Comite d'Evaluation et de Diffusion des Innovations Technologiques Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database (...) . Citation Comite d'Evaluation et de Diffusion des Innovations Technologiques. Transurethral microwave thermotherapy (TUMT) for benign prostatic hyperplasia. Paris: Comite d´Evaluation et de Diffusion des Innovations Technologiques (CEDIT). 00-03. 2000 Authors' objectives This report aims to estimate the value of transurethral microwave thermotherapy (TUMT) for benign prostatic hyperplasia (BPH) in terms of efficacy, safety, and economic considerations. Authors' conclusions In light of the literature

2000 Health Technology Assessment (HTA) Database.

108. Phytotherapy for benign prostatic hyperplasia

Phytotherapy for benign prostatic hyperplasia Phytotherapy for benign prostatic hyperplasia Phytotherapy for benign prostatic hyperplasia Wilt T J, Ishani A, Rutks I, MacDonald R Authors' objectives To review the efficacy and safety of phytotherapeutic compounds used to treat men with symptomatic benign prostatic hyperplasia (BPH). Searching MEDLINE (1966 to 1997), EMBASE, Phytodok and the Cochrane Library were searched; the search terms and dates (for non-MEDLINE databases) were not reported (...) effectiveness. Bibliographic details Wilt T J, Ishani A, Rutks I, MacDonald R. Phytotherapy for benign prostatic hyperplasia. Public Health Nutrition 2000; 3(4A): 459-472 PubMedID Other publications of related interest 1. Wilt TJ, Ishani A, Stark G, MacDonald R, Lau J, Mulrow C. Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. JAMA 1998;280:1604-9. 2. Andro MC. Riffaud JP. Pygeum africanum for the treatment of patients with benign prostatic hyperplasia: a review

2000 DARE.

109. [Cost-effectiveness analysis of the treatment of moderate benign prostatic hyperplasia]

[Cost-effectiveness analysis of the treatment of moderate benign prostatic hyperplasia] Analisis coste-efectividad del tratamiento de la hiperplasia prostatica benigna de grado moderado [Cost-effectiveness analysis of the treatment of moderate benign prostatic hyperplasia] Analisis coste-efectividad del tratamiento de la hiperplasia prostatica benigna de grado moderado [Cost-effectiveness analysis of the treatment of moderate benign prostatic hyperplasia] Meseguer Barros C M, Fidalgo Garcia M L (...) , Rubio Cebrian S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Three treatment strategies for patients suffering from moderate benign prostatic hyperplasia (MBPH) were analysed: watchful waiting (reducing liquids before sleeping

2000 NHS Economic Evaluation Database.

110. Finasteride: an update of its use in the management of symptomatic benign prostatic hyperplasia

Finasteride: an update of its use in the management of symptomatic benign prostatic hyperplasia Finasteride: an update of its use in the management of symptomatic benign prostatic hyperplasia Finasteride: an update of its use in the management of symptomatic benign prostatic hyperplasia Wilde MI, Goa KL Authors' objectives To overview the pharmacology of finasteride and provide an update of its clinical effects in patients with benign prostatic hyperplasia. Searching MEDLINE, EMBASE (...) and AdisBase (a proprietary database of Adis International, Auckland, New Zealand) were searched for trials published in any language since 1966 until February 1999. Search terms included finasteride combined with either prostatic hypertrophy or benign prostatic hyperplasia. Bibliographic information, including contributory unpublished data was also requested from the company developing the drug. Study selection Study designs of evaluations included in the review Inclusion of studies was mainly based

1999 DARE.

111. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. (Abstract)

The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. Finasteride is known to improve urinary symptoms in men with benign prostatic hyperplasia, but the extent to which the benefit is sustained and whether finasteride reduces the incidence of related events, including the need for surgery and the development of acute urinary retention (...) study period, 152 of the 1503 men in the placebo group (10 percent) and 69 of the 1513 men in the finasteride group (5 percent) underwent surgery for benign prostatic hyperplasia (reduction in risk with finasteride, 55 percent; 95 percent confidence interval, 41 to 65 percent). Acute urinary retention developed in 99 men (7 percent) in the placebo group and 42 men (3 percent) in the finasteride group (reduction in risk with finasteride, 57 percent; 95 percent confidence interval, 40 to 69 percent

1998 NEJM Controlled trial quality: predicted high

112. [Benign prostatic hyperplasia: diagnostic and treatment]

[Benign prostatic hyperplasia: diagnostic and treatment] Hiperplasia benigna de prostata: diagnostico y tratamiento [Benign prostatic hyperplasia: diagnostic and treatment] Hiperplasia benigna de prostata: diagnostico y tratamiento [Benign prostatic hyperplasia: diagnostic and treatment] Albisu A, Lantaron G, Lecumberri D, Pertusa C, Asua J, Baile M A Citation Albisu A, Lantaron G, Lecumberri D, Pertusa C, Asua J, Baile M A. Hiperplasia benigna de prostata: diagnostico y tratamiento. [Benign (...) prostatic hyperplasia: diagnostic and treatment] Vitoria-Gasteiz: Basque Office for Health Technology Assessment (OSTEBA). D-97-02. 1997 Authors' objectives

To assess the effectiveness and cost of different methods used in the diagnosis and treatment of benign prostatic hyperplasia.

Authors' conclusions In accordance with the available scientific evidence, watchful waiting and surgery (when necessary or requested by the patient), are recommended as the best option from the cost-effectiveness

1997 Health Technology Assessment (HTA) Database.

113. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. (Abstract)

The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. Men with benign prostatic hyperplasia can be treated with alpha 1-adrenergic-antagonist drugs that relax prostatic smooth muscle or with drugs that inhibit 5 alpha-reductase and therefore reduce tissue androgen concentrations. However, the effects of the two types of drugs have not been compared.We compared the safety and efficacy (...) of placebo, terazosin (10 mg daily), finasteride (5 mg daily), and the combination of both drugs in 1229 men with benign prostatic hyperplasia. American Urological Association symptom scores and peak urinary-flow rates were determined at base line and periodically for one year.The mean changes from base line in the symptom scores in the placebo, finasteride, terazosin, and combination-therapy groups at one year were decreases of 2.6, 3.2, 6.1, and 6.2 points, respectively (P<0.001 for the comparisons

1996 NEJM Controlled trial quality: uncertain

114. An economic evaluation of finasteride for treatment of benign prostatic hyperplasia

An economic evaluation of finasteride for treatment of benign prostatic hyperplasia An economic evaluation of finasteride for treatment of benign prostatic hyperplasia An economic evaluation of finasteride for treatment of benign prostatic hyperplasia Baladi J F, Menon D, Otten N Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Using 5 alpha-reductase inhibitor finasteride versus transurethral resection of the prostate (TURP), and watchful waiting (periodic monitoring of a patient by his physician, representing the "do nothing" option) in the treatment of patients (older men) with benign prostatic hyperplasia (BPH). Type of intervention Treatment. Economic study type Cost-effectiveness analysis and cost-utility analysis

1996 NHS Economic Evaluation Database.

115. Incorporating clinical effectiveness debates into hospital technology assessment: The case of laser treatment of benign prostatic hyperplasia

Incorporating clinical effectiveness debates into hospital technology assessment: The case of laser treatment of benign prostatic hyperplasia Incorporating clinical effectiveness debates into hospital technology assessment: The case of laser treatment of benign prostatic hyperplasia Incorporating clinical effectiveness debates into hospital technology assessment: The case of laser treatment of benign prostatic hyperplasia Bassett K, Kazanjian A Record Status This is a bibliographic record (...) of a published health technology assessment. The agency responsible for the publication has subsequently been disbanded. No evaluation of the quality of this assessment has been made for the HTA database. Citation Bassett K, Kazanjian A. Incorporating clinical effectiveness debates into hospital technology assessment: The case of laser treatment of benign prostatic hyperplasia. British Columbia Office of Health Technology Assessment (BCOHTA). B. C. Office of Health Technology Assessment Discussion Paper

1996 Health Technology Assessment (HTA) Database.

116. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials

Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials Boyle P, Gould A L, Roehrborn C G Authors' objectives To examine whether (...) ) or a combination of these two drugs used for at least 12 months. Participants included in the review Men (n=2,741) with clinical benign prostatic hyperplasia (BPH) (size greater than 30 mL by palpation required), and within the age range 40 to 83 years. There is a wide range of variation between studies for baseline prostate volume, baseline peak urinary flow rate and baseline symptom severity score, due to the difference in entry criteria. The mean prostate volume varies by more than 50% (or 22 mL) between

1996 DARE.

117. The cost-effectiveness of terazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia

The cost-effectiveness of terazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia The cost-effectiveness of terazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia The cost-effectiveness of terazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia Hillman A L, Schwartz J S, Willian M K, Peskin E, Roehrborn C G, Oesterling J E, Mason M F, Maurath C J, Deverka P A, Padley R J Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Terazosin in the treatment of moderate to severe benign prostatic hyperplasia. Type of intervention Treatment; palliative care. Economic study type Cost-effectiveness analysis. Study population Patients 55

1996 NHS Economic Evaluation Database.

118. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate. (Abstract)

A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate. Transurethral resection of the prostate is the most common surgical treatment for benign prostatic hyperplasia. We conducted a multicenter randomized trial to compare this surgery with watchful waiting in men with moderate symptoms of benign prostatic hyperplasia.Of 800 men over the age of 54 (...) most bothered by urinary symptoms at base line.For men with moderate symptoms of benign prostatic hyperplasia, surgery is more effective than watchful waiting in reducing the rate of treatment failure and improving genitourinary symptoms. Watchful waiting is usually a safe alternative for men who are less bothered by urinary difficulty or who wish to delay surgery.

1995 NEJM Controlled trial quality: predicted high

119. Randomised, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. Beta-sitosterol Study Group. (Abstract)

Randomised, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. Beta-sitosterol Study Group. Medical treatments have become available for benign hypertrophy of the prostate, including alpha-receptor blocking agents and 5-alpha-reductase inhibitors. Drugs derived from plants, for which no precise mechanism of action has been described, are widely used for this purpose in Europe. In a randomised, double-blind, placebo-controlled (...) multicentre study, 200 patients (recruited between April and October 1993) with symptomatic benign prostatic hyperplasia were treated with either 20 mg beta-sitosterol (which contains a mixture of phytosterols) three times per day or placebo. Primary end-point was a difference of modified Boyarsky score between treatment groups after 6 months; secondary end-points were changes in International Prostate Symptom Score (IPSS), urine flow, and prostate volume. Modified Boyarsky score decreased significantly

1995 Lancet Controlled trial quality: predicted high

120. Treatment of benign prostatic hyperplasia in Australia - some economic considerations

Treatment of benign prostatic hyperplasia in Australia - some economic considerations Treatment of benign prostatic hyperplasia in Australia - some economic considerations Treatment of benign prostatic hyperplasia in Australia - some economic considerations Hailey D, Dankiw W, Coochey J Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation (...) Hailey D, Dankiw W, Coochey J. Treatment of benign prostatic hyperplasia in Australia - some economic considerations. Australian Health Technology Advisory Committee (AHTAC). 1995 Authors' objectives To provide preliminary estimates of the cost to health programs of treating BPH using different options, and of the cost of BPH to the community. Authors' conclusions The estimates suggest that use of thermotreatment and lasers may offer an advantage over TURP. However, the results are sensitive

1995 Health Technology Assessment (HTA) Database.